DOI:
10.1055/s-00000002
Aktuelle Dermatologie
LinksClose Window
References
Kim YN, Bagot M, Pinter-Brown L. et al.
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomized, controlled phase 3 trial.
The Lancet Oncology 2018;
19: 1192-1204
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.